Company Directory

Global viral vector CDMO for cell and gene therapy

Oxford Biomedica (OXB) is a global contract development and manufacturing organisation specialising in viral vectors for cell and gene therapy. The company provides lentiviral, adeno-associated virus (AAV), and adenoviral vector development and manufacturing services from early-stage process development through to commercial-scale GMP manufacture. OXB is headquartered in Oxford and operates manufacturing sites across Oxfordshire, France, and the United States.

Manufacturing and laboratory services for diagnostic innovators

Biofortuna is a contract development and manufacturing organisation providing assay development, lyophilisation, contract manufacturing, and controlled-environment storage services to the in vitro diagnostics, point-of-care, and life science sectors. Operating from ISO 13485-certified, ISO 17025-accredited, FDA-registered facilities in Deeside, the company develops and manufactures molecular assays including PCR and LAMP formats, as well as immunoassays, in lyophilised formats for ambient-temperature distribution. Additional services include cell line quality control testing, DNA extraction, biobanking, and stability storage.

Pharmaceutical formulation development and clinical manufacturing services

SGS Quay Pharma is a contract development and manufacturing organisation providing formulation development, analytical services, and clinical trial manufacturing for pharmaceutical and biotechnology companies. The company specialises in dosage form design for APIs with challenging solubility and bioavailability profiles, and in modified and controlled release formulations. Operating from a MHRA and FDA-approved facility in North Wales, it supports clients from preclinical stage through to Phase III and commercial manufacture.

Cell-based quality control materials for immunohistochemistry and ISH

HistoCyte Laboratories is a developer and manufacturer of cell-based quality control materials for immunohistochemistry and in situ hybridisation. Its products use proprietary cell line processing technology to produce formalin-fixed, paraffin-embedded control slides and blocks with reproducible, well-characterised biomarker expression for targets including HER2, ER and PR. The company serves diagnostic laboratories, biotech and pharmaceutical companies, and offers contract services including custom cell line development and biomarker assessment.

Enzymatic synthetic DNA manufacture for gene therapy and molecular biology

NunaBio is a specialist DNA synthesis company developing a cell-free enzymatic platform for scalable production of synthetic DNA, including long oligonucleotides, whole genes and DNA fragments. Its technology avoids the plasmid and primer-dependent steps that constrain conventional phosphoramidite chemistry, enabling higher accuracy and length at reduced cost. Applications span gene therapy, T cell engineering, viral vector synthesis, mRNA therapeutics, diagnostics and DNA data storage.

Lyophilisation equipment, CDMO services, and freeze-drying expertise

Biopharma Group is a contract development and manufacturing organisation and capital equipment supplier specialising in lyophilisation and liquid formulation technologies. The company serves pharmaceutical, biotechnology, and diagnostics clients across two divisions: an equipment sales and technical service division supplying freeze dryers, aseptic fill-finish lines, and cryogenic storage systems; and a CDMO division providing formulation development, cycle development, and GMP and non-GMP contract manufacturing.

Recombinant antibody sequencing, engineering and manufacturing services

Absolute Antibody specialises in recombinant antibody technology, offering sequencing, engineering and production services alongside a catalogue of recombinant antibodies and Fc fusion proteins in a range of formats. The company's ISO 9001:2015-certified manufacturing facility serves pharmaceutical, biotechnology, diagnostics and academic customers across more than 65 countries. Absolute Antibody operates as part of Vector Laboratories following a 2024 merger, and retains its independent brand and UK manufacturing operations.

Medical-grade collagen biomaterials for regenerative medicine devices

Evergen develops, manufactures, and supplies medical-grade collagen biomaterials and engineered tissue scaffolds for use in medical devices and regenerative medicine. Operating from Glasgow under GMP conditions, the company partners with OEM medical device manufacturers to develop and supply collagen formulations including solutions, gels, films, membranes, and sponges. Applications include orthopaedics, cardiovascular repair, wound care, plastic surgery, and spinal surgery. The company provides contract manufacturing, technology transfer, and regulatory support services.

Modular automated RNA manufacturing platform

Centillion is a UK biotech company whose platform integrates synthesis, purification, and formulation stages using continuous flow chemistry to produce mRNA and self-amplifying RNA at research and production scale. The platform supports process development through to regulatory-ready CMC packages and is available as a service, under licence, or through joint development programmes. First GMP installation was completed at Quotient Sciences in Alnwick in 2024.

Integrated formulation, GMP manufacture and Phase I clinical trials

BDD Pharma is a contract research and manufacturing organisation offering an integrated Lean Clinical Development pathway that combines formulation development, GMP manufacture, and Phase I clinical trials under one roof. The approach eliminates handoffs between separate service providers, reducing time to first-in-human data. BDD also develops its own drug delivery technologies, including a patented delayed-release oral tablet system. The company operates from two Glasgow sites and serves pharmaceutical clients globally.

Ovine polyclonal therapeutics developer and antivenom manufacturer

MicroPharm is a specialty pharmaceutical company developing and manufacturing ovine polyclonal antibody therapeutics for the treatment of acute toxic and infectious conditions. The company's MHRA-licensed facilities in West Wales produce a portfolio of clinical-grade antivenoms, including products acquired from Sanofi Pasteur in 2024. Pipeline assets include an orally delivered polyclonal antibody therapy for Clostridioides difficile infection currently in Phase I clinical development. MicroPharm also provides contract development, manufacturing, and sterile filling services to third parties.

Plant-based expression platform for recombinant protein production

Bright Biotech is a UK CDMO developing and applying a proprietary plant-based expression system for the production of recombinant proteins. Its platform uses chloroplast engineering in tobacco plants to express high yields of target proteins, offering an animal-free and scalable alternative to conventional cell-based manufacturing. It supplies recombinant growth factors to the life sciences and agri-food sectors, with applications in regenerative medicine and cultivated meat production.